Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.45 |
| ▸ | HTR2C | P28335 | 11/20 | 0.45 |
| ▸ | HTR2B | P41595 | 11/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386590 | 0.79 | HTR2C (0.40) | HTR2AHTR2CHTR2BCYP3A4DPP4 | |
| SCHEMBL20556025 | 0.79 | DPP4 (0.41) | HTR2AHTR2CHTR2BDPP4DPP7 | |
| SCHEMBL794507 | 0.76 | DPP4 (0.43) | HTR2AHTR2CHTR2BDPP4DPP7 | |
| SCHEMBL2385456 | 0.76 | TACR1 (0.53) | HTR2AHTR2CHTR2BTACR1 | |
| SCHEMBL2386164 | 0.76 | DPP4 (0.47) | HTR2AHTR2CHTR2BDPP4DPP7 | |
| SCHEMBL1693684 | 0.75 | HTR2C (0.42) | HTR2AHTR2CHTR2BDPP4DPP7 | |
| Hydrochloric Acid SCHEMBL28773228 | 0.74 | DPP4 (0.46) | HTR2AHTR2CHTR2BDPP4DPP7 | |
| SCHEMBL16462634 | 0.73 | MAOA (0.42) | HTR2AHTR2CHTR2BDPP4DPP7 | |
| SCHEMBL20555983 | 0.73 | DPP4 (0.36) | HTR2AHTR2CHTR2BDPP4DPP7 | |
| SCHEMBL13860379 | 0.73 | DPP4 (0.43) | HTR2AHTR2CHTR2BDPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | HTR2A 2212/4885HTR2C 2851/4885HTR2B 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.